| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Haematology, The Royal London Hospital, Whitechapel, London E1 1BB, United Kingdom.
2 School of Biological Sciences, Queen Mary (University of London), London E1 4NS, United Kingdom.
3 Laboratory Testing Segment, Diagnostics Division, Bayer Corporation, Tarrytown, NY 10591.
aAuthor for correspondence. Fax 44-0207-377-7016; e-mail M.G.Macey{at}mds.qmw.ac.uk.
Background: Monitoring of platelet activation by the ADVIA® 120 Hematology System requires an anticoagulant and protocol that ensures that platelets are sphered and their activation status is not altered artifactually in vitro.
Methods: Blood from healthy controls was collected into tripotassium EDTA; citrate, theophylline, adenosine, and dipyridamole (CTAD); or a combination of both (E/C) and stored at ambient temperature or at 4 °C (E/C only) and then analyzed between 0 and 180 min later on the ADVIA 120. In addition, immunofluorescent flow cytometry was used to identify activated platelets and platelet-leukocyte aggregates.
Results: In blood stored with all three anticoagulants, the platelet count changed little, but the mean platelet volume (MPV) at first decreased and then increased, whereas the mean platelet component (MPC; an indicator of activation) changed in a reciprocal manner. The changes in MPV and MPC, which reflect platelet sphering and swelling, were greatest between 30 and 60 min in blood stored at ambient temperature, irrespective of which anticoagulant was used, and between 60 and 180 min when blood anticoagulated with E/C was stored at 4 °C. In all anticoagulants, the percentages of platelets expressing CD62P and of leukocytes in platelet-leukocyte aggregates increased significantly (P <0.01) over 180 min at ambient temperature. Only minimal (<2%) increases occurred when blood with E/C was stored at 4 °C.
Conclusions: When determining platelet activation ex vivo on the ADVIA 120, blood should be collected into E/C, stored at 4 °C, and analyzed between 60 and 180 min later; these conditions ensure maximum platelet sphering without concurrent artifactual platelet activation.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  P. Saravanan, A. R. Exley, K. Valchanov, N. D. Casey, and F. Falter Impact of xenon anaesthesia in isolated cardiopulmonary bypass on very early leucocyte and platelet activation and clearance: a randomized, controlled study Br. J. Anaesth., December 1, 2009; 103(6): 805 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ohkawa, K. Nakamura, S. Okubo, S. Hosogaya, Y. Ozaki, M. Tozuka, N. Osima, H. Yokota, H. Ikeda, and Y. Yatomi Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parameters Ann Clin Biochem, July 1, 2008; 45(4): 356 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hosogaya, Y. Yatomi, K. Nakamura, R. Ohkawa, S. Okubo, H. Yokota, M. Ohta, H. Yamazaki, T. Koike, and Y. Ozaki Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity Ann Clin Biochem, July 1, 2008; 45(4): 364 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zimmermann, J. Koenig, J. Zingsem, V. Weisbach, E. Strasser, J. Ringwald, and R. Eckstein Effect of Specimen Anticoagulation on the Measurement of Circulating Platelet-Derived Growth Factors Clin. Chem., December 1, 2005; 51(12): 2365 - 2368. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
